The net proceeds to Abiomed from the offering were approximately $41.7 million, after deducting the underwriting discount and estimated offering expenses. Morgan Stanley & Co was the sole underwriter for the offering.
The net proceeds to Abiomed from the offering were approximately $41.7 million, after deducting the underwriting discount and estimated offering expenses. Morgan Stanley & Co was the sole underwriter for the offering.